Literature DB >> 20490517

[How closely does rheumatology treatment follow the guidelines?: ambition and reality].

A Zink1, D Huscher, M Schneider.   

Abstract

In 2005, the first evidence-based German guideline on the management of early rheumatoid arthritis (RA) was published. With data from the national database of the German Collaborative Arthritis Centres and other health care studies we evaluated to what extent current health care is in accordance with the guideline's recommendations.A total of 66% of all newly referred RA patients seen at the national database centers in 2008 achieved the goal of seeing a rheumatologist within 3 months of symptom onset, while 75% were seen within 6 months. Before referral, 25% of the patients had DMARD therapy and 19% glucocorticoids. Of the patients in rheumatological care, 90% received DMARDs. The availability of early arthritis clinics determines the promptness of access to a rheumatologist.After 6 years of rheumatological care, around 80% of patients continuously seen were still under treatment with a conventional or biological DMARD. The highest continuation rates were seen for methotrexate monotherapy. Biologic agents were given in 2008 to 20% of patients. Of those with "severe" or "very severe" disease, 42% received biologics and 21% DMARD combination therapy. Low-dose glucocorticoids are the standard of care; of patients in rheumatological care, 88% received dosages up to 7.5 mg/d and 74% of up to 5 mg/d.

Entities:  

Mesh:

Year:  2010        PMID: 20490517     DOI: 10.1007/s00393-009-0522-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  13 in total

1.  Guidelines for the management of rheumatoid arthritis: 2002 Update.

Authors: 
Journal:  Arthritis Rheum       Date:  2002-02

Review 2.  Systematic review of rheumatoid arthritis patient education.

Authors:  Robert P Riemsma; Erik Taal; John R Kirwan; Johannes J Rasker
Journal:  Arthritis Rheum       Date:  2004-12-15

Review 3.  The BeSt story: on strategy trials in rheumatoid arthritis.

Authors:  Naomi B Klarenbeek; Cornelia F Allaart; Pit J S M Kerstens; Tom W J Huizinga; Ben A C Dijkmans
Journal:  Curr Opin Rheumatol       Date:  2009-05       Impact factor: 5.006

4.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

5.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

Authors:  Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans
Journal:  Arthritis Rheum       Date:  2005-11

6.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

7.  Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines.

Authors: 
Journal:  Arthritis Rheum       Date:  1996-05

Review 8.  Developments in the scientific understanding of rheumatoid arthritis.

Authors:  Jörg J Goronzy; Cornelia M Weyand
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

Review 9.  Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention.

Authors:  M A Quinn; P Emery
Journal:  Clin Exp Rheumatol       Date:  2003 Sep-Oct       Impact factor: 4.473

Review 10.  Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility.

Authors:  M F Bakker; J W G Jacobs; S M M Verstappen; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 27.973

View more
  10 in total

Review 1.  [Long-term trends in rheumatology care : Achievements and deficits in 25 years of the German national rheumatology database].

Authors:  K Albrecht; J Callhoff; A Zink
Journal:  Z Rheumatol       Date:  2019-10       Impact factor: 1.372

2.  Quality of care of rural rheumatoid arthritis patients in Austria.

Authors:  Rudolf Puchner; Hans Peter Brezinschek; Manfred Herold; Thomas Nothnagl; Andrea Studnicka-Benke; Josef Fritz; Burkhard F Leeb
Journal:  Wien Klin Wochenschr       Date:  2014-03-28       Impact factor: 1.704

3.  [Diagnostic spectrum, treatment indication and symptom duration in initial referrals to the rheumatologist].

Authors:  G Westhoff; E Edelmann; J Kekow; A Zink
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

Review 4.  [Treat-to-target from the perspective of office-based rheumatology].

Authors:  K Krüger; K Karberg
Journal:  Z Rheumatol       Date:  2011-10       Impact factor: 1.372

5.  [Healthcare research in rheumatology. Current state].

Authors:  A Zink
Journal:  Z Rheumatol       Date:  2014-03       Impact factor: 1.372

6.  [Cornerstones of quality assurance in medicine in Germany. Important impulse for the situation in treatment of rheumatism].

Authors:  J Braun; M Schneider; H-J Lakomek
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

7.  Rate of Proven Rheumatic Diseases in a Large Collective of Referrals to an Outpatient Rheumatology Clinic Under Routine Conditions.

Authors:  Martin Feuchtenberger; Axel Philipp Nigg; Michael Rupert Kraus; Arne Schäfer
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2016-10-02

8.  Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany.

Authors:  C Gissel; G Götz; H Repp
Journal:  Z Rheumatol       Date:  2016-12       Impact factor: 1.372

9.  Treatment preferences in juvenile idiopathic arthritis - a comparative analysis in two health care systems.

Authors:  Boris Hugle; Johannes-Peter Haas; Susanne M Benseler
Journal:  Pediatr Rheumatol Online J       Date:  2013-01-15       Impact factor: 3.054

10.  Cost per responder of TNF-α therapies in Germany.

Authors:  Christian Gissel; Holger Repp
Journal:  Clin Rheumatol       Date:  2013-07-23       Impact factor: 2.980

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.